Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis

Paricalcitol and cinacalcet have been recommended to reduce parathyroid hormone (PTH) levels for patients with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), and they are able to reduce the risk of hypercalcemia and hyperphosphatemia. However, to date, it has remained uncerta...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wei, Gong, Lifeng, Lu, Jingkui, Tang, Weigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444362/
https://www.ncbi.nlm.nih.gov/pubmed/32855693
http://dx.doi.org/10.3892/etm.2020.9044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444362/
https://www.ncbi.nlm.nih.gov/pubmed/32855693
http://dx.doi.org/10.3892/etm.2020.9044

Ejemplares similares